Titre : Uridine diphosphate

Uridine diphosphate : Questions médicales fréquentes

Termes MeSH sélectionnés :

Angiotensin II Type 2 Receptor Blockers
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Uridine diphosphate : Questions médicales les plus fréquentes", "headline": "Uridine diphosphate : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Uridine diphosphate : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-22", "dateModified": "2025-04-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Uridine diphosphate" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Nucléotides uridyliques", "url": "https://questionsmedicales.fr/mesh/D014500", "about": { "@type": "MedicalCondition", "name": "Nucléotides uridyliques", "code": { "@type": "MedicalCode", "code": "D014500", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Uridine diphosphate ose", "alternateName": "Uridine Diphosphate Sugars", "url": "https://questionsmedicales.fr/mesh/D014539", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate ose", "code": { "@type": "MedicalCode", "code": "D014539", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Uridine diphosphate N-acétylgalactosamine", "alternateName": "Uridine Diphosphate N-Acetylgalactosamine", "url": "https://questionsmedicales.fr/mesh/D014536", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate N-acétylgalactosamine", "code": { "@type": "MedicalCode", "code": "D014536", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.100" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate N-acétylglucosamine", "alternateName": "Uridine Diphosphate N-Acetylglucosamine", "url": "https://questionsmedicales.fr/mesh/D014537", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate N-acétylglucosamine", "code": { "@type": "MedicalCode", "code": "D014537", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.120" } } }, { "@type": "MedicalWebPage", "name": "Acide uridine diphosphate N-acétylmuramique", "alternateName": "Uridine Diphosphate N-Acetylmuramic Acid", "url": "https://questionsmedicales.fr/mesh/D014538", "about": { "@type": "MedicalCondition", "name": "Acide uridine diphosphate N-acétylmuramique", "code": { "@type": "MedicalCode", "code": "D014538", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.150" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate galactose", "alternateName": "Uridine Diphosphate Galactose", "url": "https://questionsmedicales.fr/mesh/D014531", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate galactose", "code": { "@type": "MedicalCode", "code": "D014531", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.300" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate glucose", "alternateName": "Uridine Diphosphate Glucose", "url": "https://questionsmedicales.fr/mesh/D014532", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate glucose", "code": { "@type": "MedicalCode", "code": "D014532", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.350" } } }, { "@type": "MedicalWebPage", "name": "Acide uridine diphosphate glucuronique", "alternateName": "Uridine Diphosphate Glucuronic Acid", "url": "https://questionsmedicales.fr/mesh/D014535", "about": { "@type": "MedicalCondition", "name": "Acide uridine diphosphate glucuronique", "code": { "@type": "MedicalCode", "code": "D014535", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.375" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate xylose", "alternateName": "Uridine Diphosphate Xylose", "url": "https://questionsmedicales.fr/mesh/D014540", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate xylose", "code": { "@type": "MedicalCode", "code": "D014540", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.800" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate", "alternateName": "Uridine Diphosphate", "code": { "@type": "MedicalCode", "code": "D014530", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Takayuki Matsumoto", "url": "https://questionsmedicales.fr/author/Takayuki%20Matsumoto", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: t-matsu@hoshi.ac.jp." } }, { "@type": "Person", "name": "Kumiko Taguchi", "url": "https://questionsmedicales.fr/author/Kumiko%20Taguchi", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan." } }, { "@type": "Person", "name": "Tsuneo Kobayashi", "url": "https://questionsmedicales.fr/author/Tsuneo%20Kobayashi", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: tkoba@hoshi.ac.jp." } }, { "@type": "Person", "name": "Rafal Jonczyk", "url": "https://questionsmedicales.fr/author/Rafal%20Jonczyk", "affiliation": { "@type": "Organization", "name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany." } }, { "@type": "Person", "name": "Thomas Hoffmann", "url": "https://questionsmedicales.fr/author/Thomas%20Hoffmann", "affiliation": { "@type": "Organization", "name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Endocytosis and signaling of angiotensin II type 1 receptor.", "datePublished": "2022-10-03", "url": "https://questionsmedicales.fr/article/36631190", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/bs.pmbts.2022.08.005" } }, { "@type": "ScholarlyArticle", "name": "Regulation of vascular angiotensin II type 1 and type 2 receptor and angiotensin-(1-7)/MasR signaling in normal and hypertensive pregnancy.", "datePublished": "2023-12-05", "url": "https://questionsmedicales.fr/article/38061417", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.bcp.2023.115963" } }, { "@type": "ScholarlyArticle", "name": "Actual impact of angiotensin II receptor blocker or calcium channel blocker monotherapy on renal function in real-world patients.", "datePublished": "2022-07-05", "url": "https://questionsmedicales.fr/article/35792108", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/HJH.0000000000003186" } }, { "@type": "ScholarlyArticle", "name": "SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway.", "datePublished": "2024-03-05", "url": "https://questionsmedicales.fr/article/38576704", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7759/cureus.55563" } }, { "@type": "ScholarlyArticle", "name": "Effect of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on need for operative intervention for idiopathic adhesive capsulitis.", "datePublished": "2023-07-03", "url": "https://questionsmedicales.fr/article/37719830", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jseint.2023.06.008" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides nucléiques, nucléotides et nucléosides", "item": "https://questionsmedicales.fr/mesh/D009706" }, { "@type": "ListItem", "position": 3, "name": "Nucléotides", "item": "https://questionsmedicales.fr/mesh/D009711" }, { "@type": "ListItem", "position": 4, "name": "Ribonucléotides", "item": "https://questionsmedicales.fr/mesh/D012265" }, { "@type": "ListItem", "position": 5, "name": "Nucléotides uridyliques", "item": "https://questionsmedicales.fr/mesh/D014500" }, { "@type": "ListItem", "position": 6, "name": "Uridine diphosphate", "item": "https://questionsmedicales.fr/mesh/D014530" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Uridine diphosphate - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Uridine diphosphate", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-02", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Uridine diphosphate", "description": "Comment diagnostiquer une carence en UDP ?\nQuels tests sont utilisés pour évaluer l'UDP ?\nL'UDP peut-il être mesuré dans le sang ?\nQuels symptômes indiquent un problème d'UDP ?\nY a-t-il des marqueurs spécifiques pour l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Uridine diphosphate", "description": "Quels sont les symptômes d'une carence en UDP ?\nL'UDP affecte-t-il le système nerveux ?\nDes douleurs musculaires peuvent-elles être liées à l'UDP ?\nL'UDP influence-t-il l'humeur ?\nY a-t-il des signes cutanés associés à l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Uridine diphosphate", "description": "Comment prévenir une carence en UDP ?\nLes suppléments sont-ils nécessaires pour l'UDP ?\nY a-t-il des groupes à risque pour l'UDP ?\nLes habitudes de vie influencent-elles l'UDP ?\nDes conseils nutritionnels existent-ils pour l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Uridine diphosphate", "description": "Comment traiter une carence en UDP ?\nLes médicaments peuvent-ils aider à l'UDP ?\nY a-t-il des thérapies alternatives pour l'UDP ?\nLes changements alimentaires sont-ils efficaces ?\nDes traitements spécifiques existent-ils pour l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Uridine diphosphate", "description": "Quelles complications peuvent survenir avec une carence en UDP ?\nL'UDP peut-il affecter le développement ?\nDes maladies chroniques sont-elles liées à l'UDP ?\nL'UDP est-il impliqué dans des maladies héréditaires ?\nDes troubles immunitaires peuvent-ils être liés à l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Uridine diphosphate", "description": "Quels sont les facteurs de risque pour l'UDP ?\nL'âge influence-t-il les niveaux d'UDP ?\nLe stress peut-il affecter l'UDP ?\nLes maladies génétiques influencent-elles l'UDP ?\nLes habitudes alimentaires jouent-elles un rôle ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une carence en UDP ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques mesurant les niveaux d'UDP dans les cellules peuvent être effectués." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'UDP ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests enzymatiques et chromatographiques sont couramment utilisés pour évaluer l'UDP." } }, { "@type": "Question", "name": "L'UDP peut-il être mesuré dans le sang ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'UDP est généralement mesuré dans les tissus plutôt que dans le sang en raison de sa faible concentration." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème d'UDP ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue, des troubles neurologiques ou des anomalies métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour l'UDP ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de marqueurs spécifiques, mais des niveaux d'enzymes peuvent indiquer des anomalies." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une carence en UDP ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles cognitifs." } }, { "@type": "Question", "name": "L'UDP affecte-t-il le système nerveux ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une carence en UDP peut entraîner des troubles neurologiques et cognitifs." } }, { "@type": "Question", "name": "Des douleurs musculaires peuvent-elles être liées à l'UDP ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs musculaires peuvent survenir en raison d'un métabolisme énergétique altéré." } }, { "@type": "Question", "name": "L'UDP influence-t-il l'humeur ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Une carence en UDP peut affecter l'humeur et entraîner des troubles de l'humeur." } }, { "@type": "Question", "name": "Y a-t-il des signes cutanés associés à l'UDP ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies cutanées peuvent apparaître, mais elles sont moins fréquentes." } }, { "@type": "Question", "name": "Comment prévenir une carence en UDP ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en acides nucléiques peut aider à prévenir une carence." } }, { "@type": "Question", "name": "Les suppléments sont-ils nécessaires pour l'UDP ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les suppléments peuvent être bénéfiques, surtout en cas de régime alimentaire pauvre." } }, { "@type": "Question", "name": "Y a-t-il des groupes à risque pour l'UDP ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des troubles métaboliques ou des régimes restrictifs sont à risque." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles l'UDP ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes de vie saines, comme l'exercice, peuvent soutenir le métabolisme de l'UDP." } }, { "@type": "Question", "name": "Des conseils nutritionnels existent-ils pour l'UDP ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, consulter un nutritionniste peut aider à élaborer un plan alimentaire adapté." } }, { "@type": "Question", "name": "Comment traiter une carence en UDP ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure des suppléments d'uridine et des modifications alimentaires." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider à l'UDP ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments peuvent améliorer le métabolisme de l'UDP, mais nécessitent une prescription." } }, { "@type": "Question", "name": "Y a-t-il des thérapies alternatives pour l'UDP ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies comme la nutrition ciblée peuvent être bénéfiques, mais nécessitent des études." } }, { "@type": "Question", "name": "Les changements alimentaires sont-ils efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en acides nucléiques peut aider à augmenter les niveaux d'UDP." } }, { "@type": "Question", "name": "Des traitements spécifiques existent-ils pour l'UDP ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de traitements spécifiques approuvés pour les troubles liés à l'UDP." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une carence en UDP ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques et métaboliques peuvent survenir si non traitées." } }, { "@type": "Question", "name": "L'UDP peut-il affecter le développement ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une carence en UDP peut nuire au développement cognitif et physique chez les enfants." } }, { "@type": "Question", "name": "Des maladies chroniques sont-elles liées à l'UDP ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies métaboliques chroniques peuvent être exacerbées par une carence en UDP." } }, { "@type": "Question", "name": "L'UDP est-il impliqué dans des maladies héréditaires ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles héréditaires du métabolisme peuvent affecter les niveaux d'UDP." } }, { "@type": "Question", "name": "Des troubles immunitaires peuvent-ils être liés à l'UDP ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une carence en UDP peut affaiblir le système immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'UDP ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les régimes alimentaires pauvres, les maladies métaboliques et le stress sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux d'UDP ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux d'UDP peuvent diminuer avec l'âge, augmentant le risque de carence." } }, { "@type": "Question", "name": "Le stress peut-il affecter l'UDP ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber le métabolisme de l'UDP et entraîner des carences." } }, { "@type": "Question", "name": "Les maladies génétiques influencent-elles l'UDP ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies génétiques peuvent affecter la synthèse et l'utilisation de l'UDP." } }, { "@type": "Question", "name": "Les habitudes alimentaires jouent-elles un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation déséquilibrée peut augmenter le risque de carence en UDP." } } ] } ] }

Sources (10000 au total)

Actual impact of angiotensin II receptor blocker or calcium channel blocker monotherapy on renal function in real-world patients.

This observational retrospective cohort study investigates the effect of antihypertensive therapy with angiotensin II receptor blockers (ARBs) or dihydropyridine calcium channel blockers (dCCBs) monot... Using propensity score matching, we selected untreated hypertensive participants ( n = 10 151) and dCCB ( n = 5078) or ARB ( n = 5073) new-users based on annual health check-ups and claims between 200... The mean age was 51 years, 79% were men and the mean estimated glomerular filtration rate (eGFR) was 78 ml/min per 1.73 m 2 . Blood pressure rapidly decreased by approximately 10% in both treatment gr... From the present findings based on the real-world data, ARBs can be recommended for kidney protection even in a primary care setting. Meanwhile, dCCB treatment initially increases eGFR with no adverse...

Effect of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on need for operative intervention for idiopathic adhesive capsulitis.

The exact pathogenesis of idiopathic adhesive capsulitis (IAC) is not fully understood, but an inflammatory profibrotic cascade, largely mediated by transforming growth factor-beta 1 (TGF- β1) has bee... This was a retrospective cohort study of patients from a single institutional database with IAC, divided into two cohorts, with and without ACE-I and/or ARB use as the primary exposure and a minimum 2... A total of 17,645 patients met inclusion criteria, with 5424 patients in the ACE-I/ARB cohort and 12,221 in the non-ACE-I/ARB cohort. Overall, 422 (2.4%) patients underwent surgical treatment, 378 (2.... Patients with IAC have an overall low (2.4%) rate of requiring surgical intervention. While the antifibrotic mechanism of ACE inhibitors and ARBs did not significantly affect the rate of requiring sur...

Angiotensin II and angiotensin II receptor 2 levels can predict shock and mortality in septic patients.

The aim of this study was to evaluate the place of angiotensin II and its receptors in the prognosis of septic patients.... Patients with sepsis and septic shock were included in the study group. The control group consisted of patients who were followed up in the ICU and had no sepsis/septic shock. Plasma angiotensin II, a... Angiotensin II levels were significantly lower in the septic shock and non-survivor. AT-1 levels were lower in all septic patients on the first day compared to the control. While AT-1 levels on the th... In septic patients, angiotensin II, AT-2 and AT-1/AT-2 levels can predict the probability of shock development and mortality....

Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers.

Angiotensin type II receptor blockers (ARBs) are the most widely used anti-hypertensive drugs. This study aimed to elucidate the likelihood and pattern of ARB-induced liver injury in a hospital-based ... Data of patients receiving fimasartan (n = 5,543), candesartan (n = 6,406), valsartan (n = 6,040), and losartan (n = 9,126) were retrieved from the clinical data warehouse of two tertiary hospitals. P... A total of 27,115 patients were enrolled, including 14,630 (54.0%) men, with a mean age of 64.6 years (standard deviation, 13.6). During 31,717 person-years of ARB therapy, serum ALT levels > 120 IU/L... Approximately 2% of patients receiving ARB therapy had significant ALT elevation (4.24/10...